EMA's CHMP recommends CAR Ts, rare disease therapies

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee.

CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a key component of this year's acquisition of Ablynx N.V. by Sanofi (Euronext:SAN; NYSE:SNY) (see "Road to Acquisition").

The committee recommended approval of Kymriah

Read the full 562 word article

User Sign In